NEW YORK (GenomeWeb) – Exiqon today announced that it has entered into an exclusive agreement with Aarhus University Hospital to license prostate cancer biomarkers discovered and validated by the hospital.

The biomarkers include gene-specific methylation patterns that are associated with the aggressiveness of prostate cancer. The epigenetic biomarkers have been validated in two independent cohorts, consisting of over 400 patients with a follow-up period of 10 years.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.